Litcius/Paper detail

Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing

DeAnna Friedman-Klabanoff, Andrea A. Berry, Mark A. Travassos, Catherine Cox, Yingjun Zhou, Annie X. Mo, Effie Nomicos, Gregory A. Deye, Marcela F. Pasetti, Matthew B. Laurens

2021Vaccine23 citationsDOIOpen Access PDF

Topics & Concepts

Circumsporozoite proteinPlasmodium falciparumVirologyRecombinant DNAMalaria vaccineImmunogenicityMedicineImmune systemBiologyImmunologyMalariaBiochemistryGeneHepatitis B Virus StudiesHIV Research and TreatmentMalaria Research and Control
Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing | Litcius